Abstract: As a malignant tumor with high incidence in men, early diagnosis and accurate staging of prostate cancer (PCa) have important clinical significance in the selection of clinical treatment plans and long-term prognosis of patients. Novel PET molecular probes based on molecularly targeted prostate-specific membrane antigen (PSMA) have shown high clinical efficacy in the diagnosis of PCa, and their development and application in the clinical setting is becoming increasingly widespread. The initial clinical application of integrated PET/MR, which combines the highly sensitive functional information of PET with the excellent soft tissue resolution of MRI, has shown its important clinical value. PSMA PET/MR has potential advantages in the diagnosis of PCa, and its research progress is reviewed here.